Status: Recruiting
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.
Participants needed: 535
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Jun 18, 2026Locations: 82
Eligibility criteria
Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in... [+16]
Participants with primary central nervous system (CNS) malignancy [+7]